| Entries |
| Document | Title | Date |
|---|
| 20080234379 | THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE PRECURSORS - Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants. | 09-25-2008 |
| 20080255234 | RUMEN PROTECTED LYSINE - Use of lysine imines and compositions containing them as a source of rumen protected lysine for ruminant animals. | 10-16-2008 |
| 20080280984 | Transdermal Delivery of Beneficial Substances Effected By a Hostile Biophysical Environment - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline. | 11-13-2008 |
| 20080319076 | COMPOSITIONS COMPRISING CREATINE SALTS AND METHODS OF USE THEREOF - The invention relates to compositions (e.g., nutritional supplements) comprising, consisting essentially of, or consisting of a creatine bicarbonate, and to methods of making and using said compositions. | 12-25-2008 |
| 20100004337 | ELECTROSTATICALLY CHARGED MULTI-ACTING NASAL APPLICATION, PRODUCT, AND METHOD - A product to reduce and method of reducing the risk of inhalation of harmful substances by applying a formulation composition to a substrate or the skin in close proximity of one or more nostrils. This formulation, when applied creates an electrostatic field having a charge. The electrostatic field attracts airborne particulates of opposite charge to the substrate that are in close proximity to the substrate close to the skin and a biocidic agent renders microorganisms coming in contact the substrate or skin less harmful. | 01-07-2010 |
| 20100113598 | HIGH DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE COMPULSIVE SPECTRUM DISORDERS - The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment. | 05-06-2010 |
| 20100280119 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 11-04-2010 |
| 20100280120 | COMPOUND INDUCING ANGIOGENESIS RESPONSE IN ISCHAEMIC TISSUES - This invention deals with a novel straight chain compound, namely, 1,6-diamino alkanoic acid having a straight chain of six carbon atoms with two terminal amino groups and accompanying —COOH group, which is capable of effecting controlled formation of new blood vessels in ischaemic tissues, and their pharmaceutically acceptable salts and/or derivatives thereof. The compounds may be in laevo, dextro, activated laevo, activated dextro or oligomeric form. The invention also pertains to a process for preparing the aforesaid novel compound, which is illustrated by the accompanying drawing. | 11-04-2010 |
| 20100286275 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR - The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 11-11-2010 |
| 20100311838 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same - The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same. | 12-09-2010 |
| 20110034558 | DP2 Antagonist and Uses Thereof - Described herein is the DP | 02-10-2011 |
| 20110166230 | Method of treating a human being for a class of neurological defects and seizure disorders - The invention involves various embodiments of a method for treating a human being for a condition associated with (1) seizures, myoclonic seizures, epilepsy, refractory epilepsy, hyperkinetic movements or tremors of hands or feet, (2) a state of ataxia, (3) accumulation of neuronal autofluorescent storage bodies in lysosomes or neurons, or regression of motor development, and (4) low alertness, dementia or mental retardation. The method involves administering a therapeutically effective salt of N-6-trimethyl-L-lysine. | 07-07-2011 |
| 20110166231 | Method of treating a human being for a class of metabolic defects and energy production disorders - The invention involves various embodiments of a method for treating a human being for a condition associated with (1) a clinical state of impairment of carnitine or carnitine esters, or decreased fatty acid metabolism, (2) low energy production or lower ATP production, (3) clinical hyperammonemia, and (4) clinically high pyruvate levels resulting from a deficiency in the biosynthesis of carnitine. The method involves administering a therapeutically effective salt of N-6-trimethyl-L-lysine. | 07-07-2011 |
| 20120016030 | METHOXYPOLYETHYLENE GLYCOL THIOESTER CHELATE AND USES THEREOF - The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl radicals or nitric oxides, or heavy metal cations. More particularly, the present invention is concerned with methoxypolyethylene glycol thioester chelate methyl esters that are useful as protectors against tissue damage by penetrating the cell membrane to remove electrons from free radical oxidants and remove heavy metals that may react with peroxides to produce the reactive hydroxyl radical, or remove Ca | 01-19-2012 |
| 20120088835 | METHODS AND COMPOSITIONS FOR TREATMENT FOR CORONARY AND ARTERIAL ANEURYSMAL SUBARACHNOID HEMORRHAGE - Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. | 04-12-2012 |
| 20120129939 | POLYAMINE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE - Disclosed herein are methods for treating a disease involving α-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α-synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Also disclosed are methods for reducing the amount of α-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α-synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods. | 05-24-2012 |
| 20120172449 | POLYAMINE TRANSPORT INHIBITORS AS NOVEL THERAPEUTICS - Novel polyamine transport inhibitors have been synthesized and demonstrated to block the uptake of native polyamines into human cancer cells. A combination therapy of the transport inhibitor and DFMO (a drug which blocks polyamine biosynthesis) provided synergistic activity against a metastatic human colon cancer cell line. The strategy uses polyamine depletion and polyamine metabolism to generate reactive oxygen species within cells as a novel way to treat cancers. This approach may be implemented for widespread use in the treatment of diseases which rely upon polyamine transport activity for proliferation. | 07-05-2012 |
| 20120184621 | METHOD FOR TREATING PHYTOPHOTODERMATITIS - A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. | 07-19-2012 |
| 20120208885 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 08-16-2012 |
| 20120252895 | THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE PRECURSORS - Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants. | 10-04-2012 |
| 20120252896 | METHODS AND COMPOSITIONS FOR MODULATION OF T-CELLS VIA THE KYNURENINE PATHWAY - The present invention provides methods for the modulation of T cells and T cell responses, particularly of Th17 effector cells. The invention provides methods of and compositions for modulating T cells, particularly T cells expressing IL-17, particularly Th17 effector cells, via the tryptophan metabolism pathway, particularly using tryptophan metabolites, kynurenines and kynurenine analogs or metabolites. The invention provides assays for screening Th17 modulators and kynurenine analogs or compounds. | 10-04-2012 |
| 20120259016 | COMPOSITIONS COMPRISING ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE FOR TREATING HEPATIC ENCEPHALOPATHY - The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy. | 10-11-2012 |
| 20130030054 | HIGHLY FLAVORED ORNITHINE-CONTAINING ALCOHOL-FREE MALT BEVERAGE - An object of the present invention is to provide an ornithine-containing alcohol-free malt beverage which is provided with health functions of ornithine imparted to an alcoholic beverage-flavored alcohol-free malt beverage containing substantially no alcohol component and which retains an excellent flavor of the alcohol-free malt beverage, and to provide a method for producing the same. The ornithine-containing alcohol-free malt beverage of the present invention is produced using ornithine hydrochloride and ornithine aspartate in combination as ornithine raw materials. For this production, 20% or more by weight of ornithine hydrochloride in terms of ornithine is used with respect to the total weight of ornithine hydrochloride and ornithine aspartate in terms of ornithine. The ornithine-containing alcohol-free malt beverage thus produced is provided with health functions of ornithine and retains an excellent flavor of an alcohol-free malt beverage. In this way, the object can be attained. In the present invention, an organic acid, in addition to ornithine hydrochloride and ornithine aspartate, may be added to adjust the pH value of the product. Examples of the added organic acid include one or more organic acids selected from malic acid, gluconic acid and phytic acid. | 01-31-2013 |
| 20130035390 | TREATMENT OF MULTIPLE SCLEROSIS - Disclosed are methods for treating multiple sclerosis patients that entail co-administration of effective amounts of a Ras antagonist which is farnesylthiosalicylic acid or an analog thereof, and a second active agent selected from glatiramer acetate, laquinimod and combinations thereof. Therapeutic compositions and methods of making them are also disclosed. | 02-07-2013 |
| 20130123364 | N6-(1-IMINOETHYL)-L-LYSINE FOR REGENERATION OF ALVEOLI IN LUNGS - The present invention describes the use of N | 05-16-2013 |
| 20130131174 | INJECTABLE PHARMACEUTICAL FORMULATION OF MELPHALAN - An injectable pharmaceutical formulation of Melphalan comprising a solid composition of melphalan hydrochloride lyophilized with a content of impurities up to 1.3% (p/p)and a pH buffer solution; a process to prepare said solid composition. Also a reconstituted solution of melphalan comprising a solid composition of melphalan lyophilized reconstituted wherein said solution is aqueous, a perfusion free of organic solvent and a kit. | 05-23-2013 |
| 20130197088 | Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO) - The present invention is based on the seminal discovery of a synergistic effect for combinations of oligoamines with 2-difluoromethylornithine (DFMO) for treatment of cancer. The invention provides combinations of at least one inhibitor of a histone demethylase enzyme and at least one inhibitor of ornithine decarboxylase (ODC). The invention also provides methods for treatment of cancer using such combinations and methods for altering methylation in a cell using such combinations. The invention provides that certain silenced genes can be re-expressed using combinations disclosed herein. | 08-01-2013 |
| 20130310458 | Sensors For The Detection Of Intracellular Metabolites - The present invention relates to a cell which is genetically modified with respect to its wild type and which comprises a gene sequence coding for an autofluorescent protein, wherein the expression of the autofluorescent protein depends on the intracellular concentration of a particular metabolite. | 11-21-2013 |
| 20140179783 | CITRULLINE-CONTAINING BEVERAGE - The invention provides an easy-to-drink beverage that contains citrulline, wherein the generation of bad odors due to storage or heating is suppressed. In particular, the invention provides a beverage that contains citrulline, citric acid, sodium citrate, water, and one or more supplements that are saccharides, souring agents, preservatives, colorants, flavoring agents, functional ingredients, or carbon dioxide. | 06-26-2014 |
| 20140213650 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same - The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same. | 07-31-2014 |
| 20140221488 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same - The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same. | 08-07-2014 |
| 20140329902 | LYSINE DELIVERY SYSTEMS FOR BLOOD COAGULATION - A blood coagulating device can include an absorbent body; and a hemostatic lysine composition associated with the body. The body can have a cylindrical or conical member having a first end having the hemostatic composition, the first end being configured for insertion into a nasal passageway. A method for coagulating blood can include providing a powdered hemostatic lysine composition; and applying the powdered hemostatic lysine composition to blood so as to cause the blood to coagulate and form a clot. The coagulation can occur in a nasal passageway away from a blood vessel. The method can include providing at least one absorbent member having the powdered hemostatic lysine composition; and applying the at least one absorbent member to the blood so that the powdered hemostatic lysine composition causes the blood to coagulate and clot. | 11-06-2014 |
| 20150025147 | ENHANCER FOR EATING ACTIVITY AND/OR GASTROINTESTINAL ACTIVITY - An agent for secreting ghrelin, comprising ornithine or a salt thereof as an active ingredient, an agent for enhancing eating activity, comprising ornithine or a salt thereof as an active ingredient, and an agent for enhancing gastrointestinal activity, comprising ornithine or a salt thereof as an active ingredient. | 01-22-2015 |
| 20150297546 | BLOOD FLOW PROMOTING AGENT - The present invention provides a blood flow promoting agent containing citrulline or a salt thereof and capsaicin or capsaicinoids as active ingredients, which is safe even by long-term administration, a food with health claims and a functional food affording such action, particularly, a blood flow promoting agent exhibiting an effective vasodilatory action of capsaicin at a low dose free of irritant property, which can be applied to improvement of athletic performance exhibited in relation to peripheral vasodilatation, suppression of fat accumulation, improvement of skin quality, as well as securing blood circulation in ischemic disease and the like, relaxation of blood vessel biased to coarctation due to advancing age, lifestyle-related diseases and the like, prophylaxis of arteriosclerosis, and prophylaxis of stiff neck, feeling of cold, erectile dysfunction, thrombosis and the like due to blood flow disorder. | 10-22-2015 |
| 20150359772 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE - Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction. | 12-17-2015 |
| 20160002152 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS - The invention provides novel compounds having the general formula (I) | 01-07-2016 |
| 20160015664 | Materials and Methods for Improving Lung Function and For Prevention and/or Treatment of Radiation-Induced Lung Complications - The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation. | 01-21-2016 |
| 20160096799 | OLIGOMER-AMINO ACID CONJUGATES - The invention relates to (among other things) oligomer-amino acid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated amino acid compounds. | 04-07-2016 |
| 20160136119 | DP2 ANTAGONIST AND USES THEREOF - Described herein is the DP | 05-19-2016 |
| 20160151312 | POLYAMINE TRANSPORT INHIBITORS AS NOVEL THERAPEUTICS | 06-02-2016 |
| 20160374972 | INTRAVENOUS ADMINISTRATION OF CITRULLINE DURING SURGERY - A method for administering citrulline to a patient during surgery without filtration of the hemolysis. | 12-29-2016 |
